India to United States: Methotrexate Export Trade Route
India has recorded 96 verified shipments of Methotrexate exported to United States, representing a combined trade value of $4.5M USD. This corridor is served by 14 active Indian exporters, with an average shipment value of $47.1K USD. The leading Indian exporter is EUGIA PHARMA SPECIALITIES LIMITED, which accounts for 51% of total export value with 35 shipments worth $2.3M USD. On the buying side, AUROBINDO PHARMA USA., INC, is the largest importer in United States with $778.5K USD in purchases. The top 3 suppliers — EUGIA PHARMA SPECIALITIES LIMITED, ZYDUS LIFESCIENCES LIMITED, ALEMBIC PHARMACEUTICALS LIMITED — together control of total trade value on this route. All data sourced from Indian Customs (DGFT) shipping bill records. Values reported in FOB USD.
Route Intelligence Overview
The India to United States Methotrexate corridor is one of India's established pharmaceutical export routes, with 96 shipments documented worth a combined $4.5M USD. The route is dominated by EUGIA PHARMA SPECIALITIES LIMITED, which alone accounts for roughly 51% of all export value, reflecting the consolidated nature of India's methotrexate manufacturing sector.
Across 14 active suppliers, the average shipment value stands at $47.1K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Freight is split between sea (60%) and air (40%), suggesting a mix of scheduled bulk orders and time-sensitive consignments.
Shipment activity peaks during April-June, with an average transit time of 30 days port-to-port. The route has recorded an annual growth rate of 18.7%, placing it at rank #2 among India's top methotrexate export destinations globally.
On the import side, key buyers of Indian methotrexate in United States include AUROBINDO PHARMA USA., INC,, XXDUSXXHARXXCEUXXCALXXUSAXXNC, J. KNIPPER & COMPANY and 20 others. AUROBINDO PHARMA USA., INC, is the single largest importer with 18 shipments valued at $778.5K USD.
